Figure 4 | Scientific Reports

Figure 4

From: Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis

Figure 4

Exemplary in- and output of fully automated CT-based body composition analysis (BCA). (A) Visualization of feature extraction for BCA and marker aggregation. BCA network detects the different BCA features within the chest CT scan. Those raw features are combined with bone to calculate body size-adjusted biomarkers. The tissues are encoded in colors as follows: pink: bone, yellow: muscle, orange-brown: subcutaneous adipose tissue (SAT), purple: epicardial adipose tissue (EAT), light blue: paracardial adipose tissue (PAT) and turquoise: inter- and intramuscular adipose tissue (IMAT). (B) Exemplary chest CT in axial view before (left) and after (right) elexacaftor/tezacaftor/ivacaftor therapy showing decreasing bronchiectasis wall thickening and regredient mucus impaction. (C) Exemplary chest CT in axial view showing increased proportion of subcutaneous adipose tissue (SAT, orange-brown) and increased inter- and intramuscular adipose tissue (IMAT, turquoise) after elexacaftor/tezacaftor/ivacaftor therapy.

Back to article page